KERECIS OMEGA3 Market Drug Insight

“KERECIS OMEGA3 Market Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about KERECIS OMEGA3 for Burns in the seven major markets. A detailed picture of the KERECIS OMEGA3 for Burns in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the KERECIS OMEGA3 for Burns. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the KERECIS OMEGA3 market forecast analysis for Burns in the 7MM descriptive analysis such as SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in Burns.

Drug Summary

Kerecis (formally known as Marigen) produces skin- and tissue-based products for use in surgery and for treating wounds. KERECIS OMEGA3 is intact fish skin rich in naturally occurring Omega3 polyunsaturated fatty acids. When grafted onto damaged human tissue, such as a burn or a diabetic wound, the material recruits the body’s own cells and is ultimately converted into living tissue. Kerecis has a wide range of products for the treatment of burns, includes KERECIS OMEGA3 Wound, KERECIS OMEGA3 OR, Kerecis Omega3 MicroGraft, Kerecis Omega3 GraftGuide, and Kerecis Primary Wound Spray, some of which are approved and some are not. Kerecis products utilize multiple patented fatty acid technologies to protect and regenerate tissue across two core technologies: Kerecis Omega3 Fish Skin and Kerecis Omega3 Viruxide.

Kerecis Omega3 Wound is intact, decellularized fish skin and is indicated for the treatment of partial and full-thickness wounds, along with other indications. The product is supplied in multiple shapes and sizes. The fish skin sheets contain fat, protein, elastin, glycans, and other natural skin elements.

Kerecis Omega3 OR is also indicated for the treatment of partial and full-thickness wounds, along with other indications. The product is supplied in multiple shapes and sizes. The fish skin sheets contain fat, protein, elastin, glycans, and other natural skin elements.

Kerecis Omega3 GraftGuide is an intact fish skin that addresses the unique challenges of burn healing in second-degree burns, among other indications. KERECIS OMEGA3 MicroGraft is not available in all countries and may be known by different names. Products, product names, indications, and claims vary between countries, and not all indications and claims for this product are, for example, cleared by the US FDA. KERECIS OMEGA3 GraftGuide is intact fish skin that especially addresses the challenges of burn healing and is indicated for the treatment of trauma wounds, including second-degree burns, along with other indications.

The easy-to-use graft is divided into small units that fill hard-to-reach areas, increasing the product’s effectiveness and improving healing. With a fragment size of about 0.15 cm, Kerecis Omega3 MicroGraft can easily be applied in deep wound spaces that are not accessible to meshed or unmeshed sheets. The product is approved for a range of wound conditions, including partial and full-thickness wounds; surgical and trauma wounds; and pressure, venous, and diabetic ulcers. Other wound-care products are approved in the United States and the European Union.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the KERECIS OMEGA3 description, mechanism of action, dosage and administration, research and development activities in Burns.
• Elaborated details on KERECIS OMEGA3 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the KERECIS OMEGA3 research and development activities in Burns across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around KERECIS OMEGA3.
• The report contains forecasted sales of for Burns till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Burns.
• The report also features the SWOT analysis with analyst views for KERECIS OMEGA3 in Burns.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

KERECIS OMEGA3 Analytical Perspective by DelveInsight

• In-depth KERECIS OMEGA3 Market Assessment

This report provides a detailed market assessment of KERECIS OMEGA3 for Burns in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• KERECIS OMEGA3 Clinical Assessment

The report provides the clinical trials information of KERECIS OMEGA3 for Burns covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Burns is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence KERECIS OMEGA3 dominance.
• Other emerging products for Burns are expected to give tough market competition to KERECIS OMEGA3 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of KERECIS OMEGA3 in Burns.
• Our in-depth analysis of the forecasted sales data of KERECIS OMEGA3 from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the KERECIS OMEGA3 in Burns.

Key Questions

• What is the product type, route of administration and mechanism of action of KERECIS OMEGA3?
• What is the clinical trial status of the study related to KERECIS OMEGA3 in Burns and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the KERECIS OMEGA3 development?
• What are the key designations that have been granted to KERECIS OMEGA3 for Burns?
• What is the forecasted market scenario of KERECIS OMEGA3 for Burns?
• What are the forecasted sales of KERECIS OMEGA3 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to KERECIS OMEGA3 for Burns?
• Which are the late-stage emerging therapies under development for the treatment of Burns?